公司资料
TuHURA Biosciences 股价、新闻与催化剂
- 股票代码:
- HURA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.36 USD (-0.73%)
收盘价
最后更新: 2026年11月19日
—
市值
股价为何变动
截至 2026年11月19日,HURA 下跌 0.73%,收于 $1.36。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Kintara Therapeutics was an oncology company focused on developing treatments for hard-to-treat cancers before becoming a historical ticker. Its story revolved around small-cap cancer drug development and the search for a viable late-stage asset.
所在地与行业分类
Kintara was headquartered in the United States and listed on NASDAQ. It sat in small-cap oncology biotechnology.
商业模式特征
The company depended on clinical progress, financing, and strategic focus while advancing a narrow pipeline. Investors historically watched trial updates and capital runway.
生物医药行业定位
Kintara is best viewed as a historical oncology biotech name. It belonged to the class of small-cap developers where a single program could dominate the story.
未来催化剂
- Kintara is a legacy / closeout story, with catalysts limited to any strategic or asset-resolution update. There is no live standalone pipeline story left.
近期新闻
新闻标题由机器翻译,详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。
